

EuroSIDA Newsletter

May 2014



ANNOUNCEMENTS

EuroSIDA Cohort X

We are **ready to begin enrolment** into the new EuroSIDA cohort, which will consist solely of HIV/HCV-coinfected individuals. The goal is to enrol a total of 5.000 new patients. Data for patients in the new cohort will be **registered electronically only**, using the online CRF system RedCap. This means that all PIs and sub-investigators will soon receive a **personal RedCap password** by email. Should you not receive an email and a password by the end of May, please check your spam filter and otherwise contact the coordinating centre for help. Those already submitting electronically can continue to do so in the usual way.

We realise that cohort X is slightly different from the previous cohorts and that there may be difficulties with the electronic data collection. Should you have any questions, please do not hesitate to contact the coordinating center at eurossida@cphiv.dk or Lars Peters at lpe@cphiv.dk. We are happy to help getting everything up and running!

New hepatitis C treatment form

For patients already enrolled in EuroSIDA, we also request that an **electronic treatment form is filled out if the patient starts treatment for HCV infection**. Completion of a treatment form will be reimbursed with €50. Please see the cover letter for Dataset 40 for more information.

Co-authorships

As a recognition of the substantial amount of work that all collaborating partners put into EuroSIDA, the steering committee has decided to **increase the number of co-authorships** for all future articles from 10 to 12. A co-authorship implies that all co-authors must comment on the paper, according to the Vancouver definition of authors. More information about co-authorships can be found at <http://www.icmje.org>.

Principle investigators

Please remember to inform the Coordinating Center if there are any **changes of principle investigators** or other collaborating partners. Also, please inform us if there are changes to contact details so that we can keep our database up to date.

Celebration

In 2014 we are proud to celebrate two great achievements: our **200th publication and EuroSIDA's 20th anniversary**. Thank you to all collaborating partners, who have helped reaching these milestones!

PUBLICATIONS

Total EuroSIDA Publications as of May 2014: 204
Publications since January 2014

Dataset

40

Dataset 40 will be **sent out in June 2014**. If you have any questions, please don't hesitate to contact the EuroSIDA team: EuroSIDA@cphiv.dk

Reimbursement of all follow-up forms is every year in October.

Monitoring

During May and June we will be doing most of the 2014 monitoring visits. We are looking forward to meeting you on the sites!

Plasma

samples

Please remember to keep a record of all plasma samples that are sent, as well as their placement in the grid boxes, so that each sample can be identified correctly. When ready to ship samples, please contact Annette Hauberg Fischer at ahf@cphiv.dk.

Questions?

For questions or help, please do not hesitate to contact the coordinating center!

E-mail: eurossida@cphiv.dk

Tel: +45 35 45 57 57

Update

from

EuroCoord

Please find the latest from EuroCoord at: newsletter at www.eurocoord.net



A comparison of estimated glomerular filtration rates (eGFRs) using Cockcroft-Gault (CG) and the CKD-EPI estimating equations in HIV infection. Mocroft A1, Ryom L, Reiss P, Furrer H, D'Arminio Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren JD, Kirk O; EuroSIDA in EuroCOORD. HIV Med 2014 Mar;15(3):144-52.

Increased incidence of antiretroviral drug discontinuation among patients with viremic HCV coinfection and high hyaluronic acid, a marker of liver fibrosis. D Grint, L Peters, J Rockstroh, S de Wit, VM Mitsura, B Knysz, C Pedersen, O Kirk, JD Lundgren, A Mocroft for EuroSIDA in EuroCoord. AIDS 2014 Feb 20;28(4):577-87

Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons in the D:A:D study. Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, Morlat P, Moranne O, Smith C, El-Sadr W, Law M, Lundgren JD for the D:A:D study group. AIDS 2014 Jan 14;28(2):187-99.

Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. L Shepherd, JC Souberbielle, JP Bastard, S Fellahi, J Capeau, J Reekie, P Reiss, A Blaxhult, M Bickel, C Leen, O Kirk, JD Lundgren, A Mocroft, JP Viard, for EuroSIDA in EuroCOORD. J Infect Dis 2014 Mar 24.

Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. A Zoufaly, A Cozzi-Lepri, J Reekie, O Kirk, J Lundgren, P Reiss, D Jevtic, L Machala, R Zangerle, A Mocroft, J van Lunzen for EuroSIDA in EuroCoord. PLoS One 2014 Jan 31;9(1)

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. DA Kamara, L Ryom, M Ross, O Kirk, P Reiss, P Morlat, O Moranne, CA Fux, A Mocroft, C Sabin, JD Lundgren, CJ Smith. BMC Nephrol. 2014 Mar 25;15(1):51.

Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Clin Infect Dis. 2014 May;58(9):1312-21.

IN PRESS

High rate of hepatitis C virus (HCV) recurrence in HIV infected individuals with spontaneous HCV-RNA clearance. L Peters, A Mocroft, V Soriano, J Rockstroh, N Kirkby, P Reiss, C Katlama, N Zakharova, R Flisiak, J Lundgren, for EuroSIDA in EuroCoord. HIV Med. In Press.

Impact of risk factors for specific causes of death in the first and subsequent years of ART among HIV infected patients. SM Ingle, MT May, MJ Gill, MJ Mugavero, C Lewden, S Abgrall, G

Fatkenheue, P Reiss, MS Saag, C Manzardo, S Grabar, M Bruyand, D Moore, A Mocroft, TR Sterling, A D'Arminio Monforte, V Hernando, R Teira, J Guest, M Cavassini, HM Crane, JA Sterne. Clin Inf Dis 2014. In Press.

Trends over time in underlying causes of death in the D:A:D study 1999-2011. C.J Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, J Kowalska, S de Wit, M Law, W el Sadr, O Kirk, N Friis-Moller, A d'Arminio Monforte, AN Phillips, CA Sabin, JD Lundgren for the D:A:D Study Group. Accepted by Lancet 2014. In Press.

A survey of ATRIPLA use in clinical practise as first line therapy IN HIV-positive persons across Europe. A Mocroft, P Reiss, A Rakhmanova, D Banhegyi, AN Phillips, S De Wit, M Ristola, JD Lundgren, J Garup, O Kirk, for EuroSIDA in EuroCoord. Infection 2014. In Press.

EuroSIDA Coordinating Centre. Rigshospitalet, University of Copenhagen. CHIP, Department of Infectious Diseases and Rheumatology, Section 2100, Finsencentret. Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.
Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: euroside@cphiv.dk
Web: www.regionh.dk www.chip.dk